Study of Oxaliplatin, Capecitabine, and Bevacizumab to Treat Older Patients With Colorectal Cancer

Geriatric Oncology Consortium

Status and phase

Terminated

Phase 2

Conditions

Neoplasm Metastasis

Colorectal Cancer

Treatments

Drug: oxaliplatin, capecitabine, bevacizumab

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00120172

GOC-GI-010

Details and patient eligibility

About

Currently there is no one standard of care for older patients with metastatic colorectal cancer. The study will examine the tumor response to capecitabine, oxaliplatin, plus bevacizumab. The study will also gather information on the usefulness and side effects of this treatment combination.

Full description

Colorectal cancer is primarily a disease of the elderly, with the median age in the United States of 70 years. Age greater than 65 years at presentation is not a contraindication to standard therapies; acceptable morbidity and mortality, as well as long term survival, are achieved in this patient population. However, studies evaluating combination therapy have generally involved younger patients with high performance status scores. Given the non-over-lapping safety profiles of the proposed study agents and the potential synergy, it would be of benefit to explore the combination of oxaliplatin, capecitabine, and bevacizumab in the treatment of older patients with colorectal cancer. Time to progression, overall response, duration of response, and toxicity profile will be evaluated. The feasibility of using a self-report geriatric assessment tool will also be assessed.

Enrollment

40 estimated patients

Sex

All

Ages

65+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age 65 years and above;
Histologically or cytologically documented adenocarcinoma of the colon or rectum;
Metastatic disease;
Measurable disease or assessable but nonmeasurable disease allowed;
ECOG 0-1
No prior oxaliplatin or bevacizumab.
No prior chemotherapy for metastatic disease. Prior adjuvant chemotherapy allowed;
No prior fluoropyrimidine therapy (unless give in an adjuvant setting and completed at least 4 months earlier);
No bleeding diathesis or coagulopathy
Adequate renal and hepatic functions as per protocol;
Signed informed consent

Exclusion criteria

Clinically significant cardiovascular or peripheral vascular disease;
Concurrent chronic aspirin, nonsteroidal anti-inflammatory drugs, warfarin, or therapeutic heparin;
Serious non-healing wound, ulcer, or bone fracture;